Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis

Pediatric Pulmonology

Volumn 21, Issue 2, 1996, Pages 77-83

  Eng, P A ^a   Morton, J ^b   Douglass, J A ^b   Riedler, J ^a   Wilson, J ^b   Robertson, C F ^c  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

cystic fibrosis; Hypertonic saline; mucolytics

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CHLORIDE; DORNASE ALFA; SALBUTAMOL; SODIUM CHLORIDE; STEROID;

ADOLESCENT; ADULT; ARTICLE; BRONCHOSPASM; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG CLEARANCE; LUNG DISEASE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MUCOCILIARY CLEARANCE; NEBULIZATION; ORAL DRUG ADMINISTRATION; PHARYNGITIS; PHYSIOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; SPUTUM; TOPICAL DRUG ADMINISTRATION; VISCOELASTICITY;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; CHILD; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; NEBULIZERS AND VAPORIZERS; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; SALINE SOLUTION, HYPERTONIC; TREATMENT OUTCOME;

EID: 0029921103     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M     Document Type: Article

References (30)

1. Harris CJ, Nadler HL. Incidence, genetics, heterozygote and antenatal detection of cystic fibrosis. In Lloyd-Still JD, ed. Textbook of Cystic Fibrosis. Boston. John Wright, 1984:1-7.
2. Wood RE, Boat TF, Doershuk CF. Cystic fibrosis, state of the art. Am Rev Respir Dis. 1976, 113:833-878.
3. Regnis JA, Robinson M, Bailey DL, Cook P, Hooper P, Chan H-K, Gonda I, Bautovitch G, Bye FTP. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am J Respir Crit Care Med. 1994; 150:66-71.
4. Phelan PDP, Olinsky A, Robertson CF. Respiratory Illness in Children. Blackwell: Oxford 1994:207-253.
5. Fiel SB. Clinical management of pulmonary disease in cystic fibrosis. Lancet. 1993; 341:1070-1074.
6. Ranasinha C, Assoufi B, Shak S, Christiansen D, Fuchs H, Empey D, Geddes D, Hodson M. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet. 1993; 342:199-202.
7. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosentstein BJ, Smith AL, Wohl ME. Effect of aerosolised recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994; 331:637-642.
8. Knowles MR, Stuns MJ, Yankaskas JR, Gatzy JT, Boucher RC. Abnormal respiratory epithelial ion transport in cystic fibrosis. Clin Chest Med. 1986; 7:285-289.
9. Frizzell RA, Rechkemmer G, Shoemaker RL. Altered regulation of airway epithelial cell chloride channels in cystic fibrosis. Science. 233:558-560.
10. + transport in cystic fibrosis respiratory epithelia: Abnormal basal rate and response to adenylate cyclase activation. J Clin Invest. 1986; 78:1245-1252.
11. Knowles MR, Church NL, Waltner WE, Yankaskas JR, Gilligan P, King M, Edwards LJ, Helms RW, Boucher RC. A pilot study of aerosolised amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med. 1990; 322:1189-1194.
12. App EM, King M, Hilfesmeder R, Kohler D, Matthys H. Acute and long term amiloride inhalation in cystic fibrosis lung disease. Am Rev Respir Dis. 1990; 141:605-612.
13. Graham A, Hasani A, Alton EWFW, Martin GP, Marriot C, Hodson ME, Clarke SW, Geddes DM. No added benefit from nebulised amiloride in patients wih cystic fibrosis. Eur Respir Jr. 1993; 6:1243-1248.
14. Folkesson HG, Kheradmand F, Matthay M. The effect of saltwater on alveolar epithelial barrier function. Am J Respir Crit Care Med. 1994; 150:1555-1563.
15. Robinson M, King M, Tomkiewicz RP, Regnis JA, Bailey DL, Peat J, Bye PTP. Effect of hypertonic saline, amiloride and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med. 1994; 149:A669.
16. Riedler J, Reade T, Button B, Robertson CF. A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. Eur Resp J. 1994; 7(S18):429.
17. Quanjer PH. Standardized lung function testing. Bull Eur Physiopathol Respir. 1983; 19(Suppl 5):1-95.
18. American Thoracic Society. Snowbird workshop on standardization of spirometry. Am Rev Respir Dis. 1979; 119:831-838.
19. Irwin RS, Curley FJ, Bennett FM. Appropriate use of antitussives and protussives. A practical review. Drugs. 1993; 46:80-91.
20. Smith CM, Anderson SD. A comparison between the airway response to isocapnic hyperventilation and hypertonic saline in subjects with asthma. Eur Respir J. 1989; 2:36-43.
21. Middleton PG, Geddes DM, Alton EW. Effect of amiloride and saline on nasal mucociliary clearance and potential difference in cystic fibrosis and normal subjects. Thorax. 1993; 48:812-816.
22. Higgenbottam T. Cough induced by changes of ion composition of airway surface liquid. Bull Eur Physiopathol Respir. 1984; 20:553-562.
23. Eschenbacher WL, Boushey HA, Sheppard D. Alteration in osmolality of inhaled aerosols cause bronchoconstriction and cough, but absence of a permanent anion causes cough only. Am Rev Respir Dis. 1984; 129:211-215.
24. Aracki H, Sly P. Inhalation of hypertonic saline as a bronchial challenge in children with mild asthma and normal children. J Allergy Clin Immunol. 1989; 84:99-107.
25. Smith CH, Anderson SD. Inhalational challenge using hypertonic saline in asthmatic subjects: A comparison with response to hyperpnoea, methacholine and water. Eur Respir J. 1990; 3:144-151.
26. Riedler J, Reade T, Dalton M, Holst D, Robertson C. Hypertonic saline challenge in an epidemiological survey of asthma children. Am J Respir Crit Care Med. 1994; 150:1632-1639.
27. Rodwell LT, Anderson SD. Hyperosmolar aerosol challenge: A useful tool in the management of subjects with cystic fibrosis. Aust N Z J Med. 1994; 24:484.
28. Mangete EDO, West D, Blankson CD. Hypertonic saline solution for wound dressing. Lancet. 1992; 340:1351.
29. Lowthian P, Oke S. Hypertonic saline solution as a disinfectant. Lancet. 1993; 341:182.
30. Mizgerd JP, Brain JD. Sodium concentration is critical to killing of Pseudomonas aeruginosa by human leucocytes: Implications for cystic fibrosis. Am J Respir Crit Care Med. 1994; 149:A665.